Ultra Market Research | Global Hidradenitis Suppurativa Market
Global Hidradenitis Suppurativa Market
Report ID : 1078
Category : Pharmaceuticals,Global
No Of Pages : 124
Published on: March 2025
Status: Published
Format :
Key Question Answer
Global Market Outlook
In-depth analysis of global and regional trends
Analyze and identify the major players in the market, their market share, key developments, etc.
To understand the capability of the major players based on products offered, financials, and strategies.
Identify disrupting products, companies, and trends.
To identify opportunities in the market.
Analyze the regional penetration of players, products, and services in the market.
Comparison of major players financial performance.
Evaluate strategies adopted by major players.
Recommendations
Global Hidradenitis Suppurativa Market Introduction Hidradenitis suppurativa (HS) is a long-standing inflammatory skin disorder with painful boils, abscesses, and tunnels under the skin, typically in the apocrine gland-containing areas. HS affects patients' quality of life and needs lifelong management. The Global Hidradenitis Suppurativa Market is growing with rising awareness, improved treatments, and mounting patient cases. The market was valued at about USD 1.4 billion in 2023 and is anticipated to expand with a CAGR of 9.79% during 2024-2030. Biologics, antibiotics, and new surgical techniques are leading to market expansion. Companies are also increasing R&D expenses to formulate targeted therapies. The launch of IL-17 and IL-23 inhibitors is a trend in the field.
Segmentation By Treatment Type • Biologic Therapies o TNF-alpha inhibitors Adalimumab Infliximab Others o IL-17 Inhibitors Secukinumab Others o IL-23 Inhibitors Risankizumab Others • Antibiotic Therapies o Oral Antibiotics Tetracyclines Clindamycin Others o Topical Antibiotics Clindamycin Gel Fusidic Acid Others • Surgical Treatments o Incision and Drainage o Laser Therapy o Electrosurgery • Others
By Disease Severity • Mild HS o Stage I o Others • Moderate HS o Stage II o Others • Severe HS o Stage III o Others
By End-User • Hospitals o Dermatology Clinics o Multispecialty Hospitals • Specialty Clinics • Research Institutes • Homecare
By Distribution Channel • Hospital Pharmacies • Retail Pharmacies • Online Pharmacies
By Geography • North America o U.S. o Canada • Europe o Germany o UK o France o Others • Asia-Pacific o China o Japan o India o Others • Latin America • Middle East & Africa
List of Market Players 1. AbbVie Inc. (United States) 2. Novartis AG (Switzerland) 3. Pfizer Inc. (United States) 4. UCB Pharma (Belgium) 5. Eli Lilly and Company (United States) 6. GlaxoSmithKline plc (United Kingdom) 7. Sanofi (France) 8. Boehringer Ingelheim (Germany) 9. Johnson & Johnson (United States) 10. Incyte Corporation (United States) 11. Sun Pharmaceutical Industries Ltd. (India) 12. AstraZeneca (United Kingdom) 13. Amgen Inc. (United States) 14. Bayer AG (Germany) 15. Regeneron Pharmaceuticals (United States)
Drivers Global Hidradenitis Suppurativa Market is spurred by various factors. The rising incidence of HS worldwide has led to increased demand for effective treatment. As per studies, HS occurs in about 1% of the population worldwide, with increased prevalence among women. The approval of drugs like Adalimumab has revolutionized treatment, offering targeted therapy for patients with moderate to severe HS. In addition, genetic research advancements and personalized medicine are opening the way for improved patient outcomes. Expanded awareness via patient advocacy initiatives and rising dermatology research funding also are contributing to market expansion. In addition, pharmaceutical companies are investing in pipeline drugs acting against inflammatory pathways that may produce breakthrough therapies. Expanding healthcare infrastructure in emerging economies is yet another key driver powering market growth.
Restraints In spite of the growth prospects, the Global Hidradenitis Suppurativa Market is confronted with a number of challenges. Low awareness and misdiagnosis of HS tend to delay treatment, aggravating patient conditions. The exorbitant price of biologic drugs such as TNF inhibitors and IL-17 inhibitors limits access, especially in lower-income countries. The absence of curative treatment options and reliance on symptom control also impede market growth. Also, severe side effects from long-term use of antibiotics become a source of concern for medical professionals and patients. The intensive drug development regulatory approval process hindering entry to the market slows down the commercialization process. Another critical factor is the stigma of HS that causes underreporting and lowers healthcare-seeking rates among patients. Insurance coverages for treatments for HS are yet to expand to many countries, further limiting entry to novel treatments.
Opportunities Global Hidradenitis Suppurativa Market has many opportunities for expansion. Rising research into new therapeutic targets like JAK inhibitors and complement system modulators could transform treatment. Increased investment in dermatology R&D is set to drive the drug development pipeline. Telemedicine and digital platforms are also bringing new opportunities for early diagnosis and remote patient care. In addition, increasing insurance cover and patient aid programs in emerging markets will increase access to care. The rise in the adoption of personalized treatment and biomarker-based therapies represents another important opportunity. Furthermore, pharmaceutical companies, in collaboration with research institutes, for HS-related clinical trials will accelerate drug discovery. Finally, increased awareness programs by healthcare entities are bound to boost early detection rates and stimulate patients to look for medical help.
Trends Global Market for Hidradenitis Suppurativa is experiencing multiple emerging trends. One of these trends is the creation of IL-17 and IL-23 inhibitors, whose clinical trials are promising. Increasing use of less invasive procedures, including laser treatments and electrosurgery, due to quicker healing times is an emerging trend. Telemedicine, along with dermatology diagnosis aided by artificial intelligence, is supporting patients in taking early consultations without allowing the spread of the disease. The growth of combination biologic therapies is another significant trend, with firms pursuing dual-targeted therapy for improved effectiveness. Patient-facing drug development is also gaining popularity, with pharmaceutical firms interacting directly with HS patients to develop personalized treatments. Gene therapy and microbiome-based therapy are also starting to emerge as future treatment options. The high-level adoption of wearable health monitoring devices is also helping in real-time disease monitoring among HS patients.
Approved & Pipeline Products • Approved Products o Adalimumab (Humira) o Infliximab (Remicade) • Pipeline/Pre-Registration Products o Secukinumab (IL-17 Inhibitor) o Risankizumab (IL-23 Inhibitor) o IFX-1 (Complement System Inhibitor) o JAK Inhibitors (Under Development)
The market was valued at USD 1.4 billion in 2023 and is expected to grow at CAGR 9.79% from 2024-2030.
Rising prevalence, increased R&D in biologics, and advancements in genetic-based therapies are major growth drivers.
High treatment costs, lack of awareness, and limited curative options pose challenges.
Key players include AbbVie, Pfizer, Novartis, Eli Lilly, and Johnson & Johnson.
The adoption of IL-17/IL-23 inhibitors, combination therapies, and telemedicine-based dermatology consultations are growing trends.
1. Introduction 1.1 Report Description 1.2 Research Methodology 1.2.1 Data Mining 1.2.2 Market Modeling and Forecasting 1.2.3 Data Validation 1.2.4 Industry Analysis
2. Market Dashboard
3. Market Overview 3.1 Market Definition and Scope 3.2 Market Segmentation 3.2.1 By Treatment Type 3.2.2 By Disease Severity 3.2.3 By Distribution Channel 3.2.4 By End-User 3.2.5 By Geography 3.3 Market Dynamics 3.3.1 Drivers 3.3.2 Restraints 3.3.3 Opportunities 3.3.4 Challenges
4. Global Hidradenitis Suppurativa Market by Treatment Type 4.1 Introduction 4.2 Market Size and Growth Rate by Treatment Type (2024-2030) 4.2.1 Pharmacological Therapies 4.2.1.1 Biologic Agents 4.2.1.2 Antibiotics 4.2.1.3 Hormonal Therapies 4.2.1.4 Others 4.2.2 Surgical Interventions 4.2.2.1 Incision and Drainage 4.2.2.2 Laser Therapies 4.2.2.3 Excisional Surgery 4.2.2.4 Others 4.2.3 Lifestyle and Supportive Treatments 4.2.3.1 Pain Management 4.2.3.2 Wound Care 4.2.3.3 Others
5. Global Hidradenitis Suppurativa Market by Disease Severity 5.1 Introduction 5.2 Market Size and Growth Rate by Disease Severity (2024-2030) 5.2.1 Mild HS 5.2.1.1 Stage I (Hurley System) 5.2.1.2 Others 5.2.2 Moderate HS 5.2.2.1 Stage II (Hurley System) 5.2.2.2 Others 5.2.3 Severe HS 5.2.3.1 Stage III (Hurley System) 5.2.3.2 Others
6. Global Hidradenitis Suppurativa Market by Distribution Channel 6.1 Introduction 6.2 Market Size and Growth Rate by Distribution Channel (2024-2030) 6.2.1 Hospital Pharmacies 6.2.1.1 Inpatient Pharmacies 6.2.1.2 Outpatient Pharmacies 6.2.1.3 Others 6.2.2 Retail Pharmacies 6.2.2.1 Chain Pharmacies 6.2.2.2 Independent Pharmacies 6.2.2.3 Others 6.2.3 Online Pharmacies 6.2.3.1 E-commerce Platforms 6.2.3.2 Direct-to-Consumer Websites 6.2.3.3 Others
7. Global Hidradenitis Suppurativa Market by End-User 7.1 Introduction 7.2 Market Size and Growth Rate by End-User (2024-2030) 7.2.1 Hospitals 7.2.1.1 Public Hospitals 7.2.1.2 Private Hospitals 7.2.1.3 Others 7.2.2 Dermatology Clinics 7.2.2.1 Specialty Clinics 7.2.2.2 General Clinics 7.2.2.3 Others 7.2.3 Homecare Settings 7.2.3.1 Patient-Administered Treatments 7.2.3.2 Caregiver-Administered Treatments 7.2.3.3 Others
8. Global Hidradenitis Suppurativa Market by Geography 8.1 Introduction 8.2 Market Size and Growth Rate by Region (2024-2030) 8.2.1 North America 8.2.1.1 United States 8.2.1.2 Canada 8.2.2 Europe 8.2.2.1 Germany 8.2.2.2 France 8.2.2.3 United Kingdom 8.2.2.4 Rest of Europe 8.2.3 Asia Pacific 8.2.3.1 China 8.2.3.2 Japan 8.2.3.3 India 8.2.3.4 Southeast Asia 8.2.3.5 Rest of Asia Pacific 8.2.4 Latin America 8.2.4.1 Brazil 8.2.4.2 Rest of Latin America 8.2.5 Middle East & Africa (MEA) 8.2.5.1 GCC 8.2.5.2 North Africa 8.2.5.3 South Africa 8.2.5.4 Rest of Middle East & Africa
9. Competitive Landscape 9.1 Company Profiles 9.1.1 Pfizer Inc. (United States) 9.1.2 AbbVie Inc. (United States) 9.1.3 Novartis AG (Switzerland) 9.1.4 Johnson & Johnson (United States) 9.1.5 AstraZeneca PLC (United Kingdom) 9.1.6 Bristol-Myers Squibb Company (United States) 9.1.7 Eli Lilly and Company (United States) 9.1.8 UCB S.A. (Belgium) 9.1.9 Amgen Inc. (United States) 9.1.10 Incyte Corporation (United States) 9.1.11 Kyowa Kirin Co., Ltd. (Japan) 9.1.12 Leo Pharma A/S (Denmark) 9.1.13 Almirall S.A. (Spain) 9.1.14 Sanofi (France) 9.1.15 Galapagos NV (Belgium)
10. List of Tables and Figures 10.1 Tables • Market Size of Global Hidradenitis Suppurativa Market (2024-2030) • Market Segmentation by Treatment Type, Disease Severity, End-User, and Geography • Market Share of Key Players • List of Approved and Pipeline Products
The process of market research at Ultra Market Research is an iterative in application and usually follows following path. Information from secondary used to build data models, then results from data models are validated from primary participants. Then cycle repeats where, according to inputs from primary participants, additional secondary research is done, and new Information is again incorporated into data model. The process continues till desired level of Information is not generated
To calculate the market size, the report considers the revenue generated from the sales of Ultra Market Research providers. The revenue generated from the sales of Ultra Market Research has been calculated through primary and secondary research. The report also presents the key players operating in the Ultra Market Research market across the globe identified through secondary research and a corresponding detailed analysis of the top vendors in the market. The market size calculation also includes distribution channel segmentation determined using secondary sources and verified through primary sources.
Secondary Research
The secondary research source that are typically referred to include, but are not limited to:
Company websites, annual reports, financial reports, broker reports, investor presentations and SEC filings
Internal and external proprietary databases, relevant patent and regulatory databases
National government documents, statistical databases and market reports
News articles, press releases and web-casts specific to the companies operating in the market
The source for secondary research includes but is not limited to: Factiva, Hoovers and Statista
Inner Circle Represents – Stage of Research Process
Middle Circle Represents – Source of Information
Outer Circle Represents – Information Derived from that source
Primary Research We conduct primary interviews on an ongoing basis with industry participants and commentators in order to validate data and analysis. A typical research interview fulfills the following functions:
It provides first-hand Information on the market size, market trends, growth trends, competitive landscape, future outlook etc.
Helps in validating and strengthening the secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves E-mail interactions, telephonic interviews as well as face-to-face interviews for each market, category, segment and sub-segment across geographies
The participants who typically take part in such a process include, but are not limited to:
Industry participants: CEOs, VPs, marketing/ distribution channel managers, market intelligence managers and national sales managers
Purchasing managers, technical personnel, distributors and resellers
Outside experts: Investment bankers, valuation experts, research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry distribution channels
Models Where no hard data is available, we use modeling and estimates in order to produce comprehensive data sets. A rigorous methodology is adopted in which the available hard data is cross referenced with the following data distribution channels to produce estimates:
Demographic data: Population split by segment
Macro-economic indicators: GDP, etc.
Industry indicators: Expenditure, distribution channel stage & infrastructure, sector growth and facilities.
Data is then cross checked by the expert panel.
2..1 Company Share Analysis Model
Company share analysis is used to derive the size of Global market. As well as study of revenues of companies for last three to five years also provide the base for forecasting the market size and its growth rate. This model is built in following steps: 2..2 Revenue Based Modeling
Revenue based models can be built in two ways – Top-Down or Bottom-Up irrespective of industry. Market size estimated from company share analysis acts as a validation point for bottom-up approach where as it acts as starting point for top-down approach.
2.1 Research Limitations Inflation is not a part of pricing in this report. Prices of Global Hidradenitis Suppurativa Market and its derivatives vary in each region and hence similar revenue ratio does not follow for each individual region. The same price for each distribution channel has been taken into account while estimating and forecasting market revenue Globally. Regional average price has been considered while breaking down this market by application in each region. This report provides market size of Global Hidradenitis Suppurativa Market for the past year and forecasts for the next six years. Global Hidradenitis Suppurativa Market size is given in terms of revenue Market revenue is defined in USD Million. Market numbers are given on the basis of different Global Hidradenitis Suppurativa Market categories. Market size and forecasts for each major application is provided in the context of Global market. The numbers provided in this report are derived on the basis of demand for Global Hidradenitis Suppurativa Market from different application industries in different regions.
Segmentation By Treatment Type • Biologic Therapies o TNF-alpha inhibitors Adalimumab Infliximab Others o IL-17 Inhibitors Secukinumab Others o IL-23 Inhibitors Risankizumab Others • Antibiotic Therapies o Oral Antibiotics Tetracyclines Clindamycin Others o Topical Antibiotics Clindamycin Gel Fusidic Acid Others • Surgical Treatments o Incision and Drainage o Laser Therapy o Electrosurgery • Others
By Disease Severity • Mild HS o Stage I o Others • Moderate HS o Stage II o Others • Severe HS o Stage III o Others
By End-User • Hospitals o Dermatology Clinics o Multispecialty Hospitals • Specialty Clinics • Research Institutes • Homecare
By Distribution Channel • Hospital Pharmacies • Retail Pharmacies • Online Pharmacies
By Geography • North America o U.S. o Canada • Europe o Germany o UK o France o Others • Asia-Pacific o China o Japan o India o Others • Latin America • Middle East & Africa
List of Market Players 1. AbbVie Inc. (United States) 2. Novartis AG (Switzerland) 3. Pfizer Inc. (United States) 4. UCB Pharma (Belgium) 5. Eli Lilly and Company (United States) 6. GlaxoSmithKline plc (United Kingdom) 7. Sanofi (France) 8. Boehringer Ingelheim (Germany) 9. Johnson & Johnson (United States) 10. Incyte Corporation (United States) 11. Sun Pharmaceutical Industries Ltd. (India) 12. AstraZeneca (United Kingdom) 13. Amgen Inc. (United States) 14. Bayer AG (Germany) 15. Regeneron Pharmaceuticals (United States)
